Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Gbiologics Inc. is currently navigating 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to a distinct examiner and a distinct art unit. The singular nature of the current prosecution suggests a focused effort on a specific biological or pharmaceutical innovation. This allows the company to concentrate its legal and technical resources on a single set of examiner requirements and art unit guidelines.
The busiest examiner, REYNOLDS, FRED H, is responsible for 1 busiest examiner pending office action. This action constitutes the entire pending workload for the company. Because there is only 1 distinct examiner involved, the company can direct its attention to the specific requirements of this examiner and the standards of the single art unit involved. Practitioners should note that the success of the company's current intellectual property strategy depends entirely on the resolution of this 1 pending office action. Engaging effectively with REYNOLDS, FRED H is the primary objective for the company's prosecution team at this stage.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REYNOLDS, FRED H | 1 | 32.9% | +39.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18037602 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING RECOMBINANT STABILIZED GALECTIN 9 PROTEIN | REYNOLDS, FRED H | 71d |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18037602 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING RECOMBINANT STABILIZED GALECTIN 9 PROTEIN | REYNOLDS, FRED H | 1658 | §103Other | Final Rejection | 71d | Pending | May 18, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGbiologics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Fred H Reynolds has the most, with 1 of Gbiologics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
